EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 868 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Fructose Fuels Cancer Growth Indirectly, Lab Study Finds January 14, 2025 Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy July 22, 2024 FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma June 26, 2020 Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO... September 20, 2021 Load more HOT NEWS Investment Needed to Bring Down Pancreatic Cancer Death Rates in Europe.... Reflections on My First Year as NCI Director 35-Year-Old Mom Has Been Living With Stage IV Breast Cancer For... Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy...
